+ Watch VRTX
on My Watchlist
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
I won't spend much time knocking telaprevir or the rest of the pipeline, as it seems there's a lot of potential there. But a market cap of 3.6 billion? In this environment for biotech? With a quarterly burn of 100 million and no marketed products? It seems a lot of projected success has already been written into the price. Any negative catalyst could send this stock right into the toilet. There's a quarterly statement in about a week as well as interim telaprevir results in May. Those interime results had better be damn good. And just one note of skepticism on the cystic fibrosis data that seemed to initiate the recent run-up: the company claims VX-770 significantly improved lung function in a 14 day study. I'm not a pulmonologist, but my understanding of cystic fibrosis is that the lung damage is mostly chronic and irreversible due to scarring from repeated infections, not an immediate consequence of the underlying genetic defect. So I'm not giving Vertex the cure for cystic fibrosis just yet, thanks.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions